Dissolution and bracketing [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2020-03-21 18:39 (1098 d 10:32 ago) – Posting: # 21292
Views: 2,627

Hi Susanh,

Can bracketing be used for additional strengths were the dissolution is not similar? Could BE-studies been done on the highest and lowest strength and not on middle strengths in this case?

Bracketing approach (when deviation from biowaiver criteria exist ) for additional strength Biowaivers is allowed according to both EMA and FDA but they differ in the principle for selecting the strengthes for which the 2 BE studies should be performed.

For EMA: Strengths selected must represent the extreme of deviation(s) from biowaiver conditions:-
Proportionality of strengths
Similarity of dissolution
Linearity of pharmacokinetics (under fasted and/or fed administration)

i.e in your case the two strength which differ in Similarity of dissolution and ( proportionality or PK linearity)

For FDA : The 2 BE-studies must be done on the highest and lowest strengthes.

Best regards,


Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
10 visitors (0 registered, 10 guests [including 5 identified bots]).
Forum time: 05:11 CET (Europe/Vienna)

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz